Segment Information (Tables)

3 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended June 30,
	2024		2023
	(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	40,414	$	60,864
Total revenue	$	40,414	$	60,864
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(8,841)	$	(5,602)
Therapeutics Adjusted EBITDA	(12,417)		(31,138)
Unallocated Corporate	(13,904)		(13,060)
Total Adjusted EBITDA	$	(35,162)	$	(49,800)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(69,400)	$	(104,624)
Adjustments:
Interest income, net	(2,574)		(4,307)
Other (income) expense, net	19		(333)
Depreciation and amortization	4,011		4,478
Amortization of acquired intangible assets	1,776		3,638
Stock-based compensation expense	21,577		51,100
Transaction costs related to disposition of Lemonaid Health (2)	—		248
Cyber security incident expenses, net of probable insurance recoveries (3)	9,429		—
Total Adjusted EBITDA	$	(35,162)	$	(49,800)

(1)There was no Therapeutics revenue for the three months ended June 30, 2024 and 2023.

(2)Refer to Note 17, “Disposition of Subsidiary” for additional information.

(3)Refer to Note 11, “Cyber Security Incident” for additional information.

Schedule of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended June 30,
	2024				2023
	(in thousands)
Consumer and Research Services Segment Revenue:
Customer C (1)(2)	$	7,577	19	%	$	9,711	16	%
Customer B (3)	$	1	—	%	$	10,670	18	%

(1)Customer C is a reseller.

(2)Customer C revenues are primarily in the United States.

(3)Customer B revenues are in the U.K.